ClinicalTrials.gg
CompletedNCT02759588Updated Jun 12, 2026Results posted

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

A Phase 1/2 interventional study of Olvi-Vec and Platinum-doublet with or without bevacizumab in Ovarian Cancer, Peritoneal Carcinomatosis and Fallopian Tube Cancer, sponsored by Genelux Corporation. Completed at 2 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Genelux Corporation · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
751st of 1,498
46 · median 47
Started
2016
with 71 others
Phase 1/2
222 of 1,779
47 open now
Registered
966th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 751st largest by enrollment of the 1,498 interventional ones that give a count, is one of 72 that started in 2016, is one of 222 in phase 1/2, and was the 966th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.

Read the detailed description

Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, Olvi-Vec, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than 30 different human tumors, including ovarian cancer. Olvi-Vec has been investigated in early stage clinical trials in the United States and Europe via systemic delivery as monotherapy and in combination with other therapies, and via regional delivery as monotherapy. Olvi-Vec treatment was well tolerated across different malignancies, routes of administration, and monotherapy as well as combination therapy protocols. The ability of Olvi-Vec to infect tumor tissue and kill tumor cells was demonstrated. In addition, virus-induced immune activation and favorable anti-tumor immune response have been observed. Evidences of anti-tumor efficacy and clinical benefits have also been documented.

03

Conditions studied

  • Ovarian Cancer
  • Peritoneal Carcinomatosis
  • Fallopian Tube Cancer

Keywords

  • Olvi-Vec
  • oncolytic virus
  • virotherapy
  • Viral therapy
  • immunotherapy
  • immune therapy
  • vaccinia
  • vaccinia virus
  • Genelux
  • ovarian cancer
  • platinum resistant
  • platinum refractory
  • peritoneal carcinomatosis
  • fallopian cancer
  • cancer
  • abdominal cancer
  • imaging
  • carcinoma
  • DNA virus
  • neoplasms
  • neoplasms by histological type
  • neoplasms, Glandular and Epithelial
  • Poxviridae infections
  • Virus diseases
  • recurrent ovarian cancer
  • intermediate platinum-sensitive
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed, written .
  • High-grade serous (including Malignant Mixed Mullerian Tumor (MMMT) with that contains high grade epithelial carcinoma), endometrioid, or clear-cell ovarian cancer which includes: (1) platinum-resistant (recurrence or progression in \< 6 months) or (2) platinum- (progression while on platinum-based therapy); patient must have failed either at least 2 consecutive therapies or are not eligible for additional cytotoxic therapies (exception is Phase 2 receiving chemotherapy with/without bevacizumab).
  • Intermediate platinum-sensitive patients (recurrence of disease 6 to 12 months from last platinum compound treatment): Recurrent ovarian carcinoma with at least four prior individual treatment regimens including at least two separate platinum-based therapies with recurrence from the last platinum-based regimen less than 12 months, who are unwilling or unable to undergo additional platinum-based cytotoxic therapy (this sub-population is not applicable for Phase 2 receiving chemotherapy with/without bevacizumab).
  • Performance status is at 0 or 1, and of 6 months
  • Has either in the peritoneal cavity as defined by 1.1 (Phase 1b \& 2) or has non-measurable disease in the peritoneal cavity (Phase 1b) and can be confirmed by laparoscopy and/or elevated CA-125. Patients who have non-measurable disease that is not identifiable by PET/PET-CT scan, but who have elevated CA-125, and/or ascites, with visible disease confirmed by laparoscopy are also eligible.
  • Able to undergo IP injection.
  • Adequate renal, hepatic, bone marrow and immune functions.
  • Baseline tumor is required.
  • Documented progressive disease status at baseline (Phase 2).

Exclusion criteria

Exclusion Criteria:

  • Tumors of mucinous subtypes, or non-epithelial ovarian cancers (e.g., Brenner tumors, Sex-cord tumors).
  • Unresolved bowel obstruction.
  • Known central nervous system (CNS) .
  • Known seropositivity for or active hepatitis infection.
  • History of thromboembolic event within the last 3 months.
  • Pregnant or breast-feeding women.
  • Smallpox vaccination within 1 year of study treatment.
  • cardiac disease.
  • Received prior gene therapy or therapy with cytolytic virus of any type.
  • Receiving concurrent antiviral agent active against vaccinia virus.
  • Have known allergy to ovalbumin or other egg products.
  • Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or unhealed skin wounds or ulcers) as assessed by the Investigator.
  • Symptomatic malignant ascites and non-manageable pleural effusion.
  • Known to bevacizumab, uncontrolled hypertension, history of stroke, or clinical findings suggestive of excessive risk for GL perforation (uncontrolled peptic ulcer disease, partial small bowel obstruction, etc.) that would make risks of bevacizumab unacceptable in the opinion of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Phase 1b - Cohort 1

    Participants treated in Cohort 1 received 2 IP infusions at 3 x 10e9 pfu.

    Biological: Olvi-Vec

  • Experimental
    Phase 1b - Cohort 2

    Participants treated in Cohort 2 received 2 IP infusions at 1 x 10e10 pfu.

    Biological: Olvi-Vec

  • Experimental
    Phase 1b - Cohort 3

    Participants treated in Cohort 3 received 2 IP infusions at 2.5 x 10e10 pfu.

    Biological: Olvi-Vec

  • Experimental
    Phase 2

    Participants treated in the Phase 2 portion received 2 IP infusions of Olvi-Vec at 3 x 10e9 pfu followed by platinum-doublet chemotherapy with or without bevacizumab.

    Biological: Olvi-Vec · Drug: Platinum-doublet with or without bevacizumab

Interventions

  • BiologicalOlvi-Vec

    Olvi-Vec is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.

    Also known as: Olvimulogene nanivacirepvec

  • DrugPlatinum-doublet with or without bevacizumab

    Drug page: Bevacizumab

    Carboplatin + choice of non-platinum chemotherapy drug: taxane, paclitaxel, nab-paclitaxel, gemcitabine or doxorubicin pegylated liposomal with or without bevacizumab.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b)

    Determine safety and tolerability of administering 2 consecutive doses of Olvi-Vec via intraperitoneal catheter by the evaluation of the number of participants with related treatment-emergent adverse events (type, frequency, and severity) as assessed by CTCAE 4.03.

    Time frame: Change from baseline during Treatment and for 30 days following last dose over average of 2 years.

  2. Progression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer.

    Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: For participants enrolled in the Phase 2 portion, outcome is from the date of starting chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  3. Overall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer

    To assess anti-tumor response by Overall Response Rate by Tumor Marker Cancer Antigen-125 (CA-125) for participants who were enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer.

    Time frame: Assessed pre-treatment, during treatment at 2- to 3-week intervals and post-treatment assessed up to 24 months.

  4. Overall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer

    To assess anti-tumor response by Overall Response Rate (ORR) defined as disease control rate (DCR = CR + PR + SD≥15 weeks) by RECIST 1.1 criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.

    Time frame: For evaluable participants enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer who were assessed at pre-treatment, during treatment at 6- to 12-week intervals and post-treatment up to 24 months.

Secondary outcomes

  1. Evaluation of Tumor Response to Treatment for Participants Enrolled in the Phase 1b Portion of This Study

    Participants enrolled in the Phase 1b study were assessed for best overall response to treatment with therapeutic intent by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.

    Time frame: Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.

  2. CA-125 Response in Participants Enrolled in the Phase 1b Portion of This Study

    CA-125 according to the Gynecologic Cancer Intergroup (GCIG) is measured by at least a 50% reduction in CA-125 levels from pre-treatment sample which is confirmed and maintained for at least 28 days. Pre-treatment CA-125 sample must be at least twice the upper limit of normal and obtained within 2 weeks prior to starting treatment.

    Time frame: Assessed pre-treatment, during treatment and post-treatment at 6 to 12 week intervals, assessed up to 24 months.

  3. Determine Progression-free Survival Following Treatment (Phase 1b)

    To assess the number of months of progression-free survival (PFS) by RECIST 1.1.

    Time frame: From the date of starting chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.

  4. Overall Survival

    To determine overall survival (OS) in the participant population.

    Time frame: By medical chart review until death or 3 years from the date of last treatment whichever comes first.

  5. Clinical Benefit Rate

    Defined as the percentage of patients who have achieved CR + PR + SD by RECIST 1.1.

    Time frame: Approximately 24 months

Other outcomes

  1. Evaluation of Immune-related Tumor Response

    This exploratory outcome measure evaluates participants' best overall response to treatment with oncolytic immunotherapy assessed by Immune-related Response Criteria (immune-related complete response, immune-related partial response, immune-related stable disease, or immune-related progressive disease).

    Time frame: Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.

07

Results

Posted Jun 12, 2026

Participant flow

Participants were enrolled at 2 clinical sites in the United States. Enrollment into cohorts based on order of consented and eligible participants into an open cohort.

Participant flow — Overall Study
MilestonePhase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C Participants
Started6512212
Completed11021
Not completed5412011
Withdrew: Death5411810
Withdrew: Lost to follow-up00010
Withdrew: Withdrawal by subject00011

Outcome measures

PrimaryNumber of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b)

Determine safety and tolerability of administering 2 consecutive doses of Olvi-Vec via intraperitoneal catheter by the evaluation of the number of participants with related treatment-emergent adverse events (type, frequency, and severity) as assessed by CTCAE 4.03.

Time frame:
Change from baseline during Treatment and for 30 days following last dose over average of 2 years.
Reported as:
Count of participants · Participants
Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b)
ParticipantsPhase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 Participants
Participants with Mild, Moderate or Severe related TEAEs551
Participants with life-threatening related TEAEs000
Participants with related TEAEs with outcome of death000
PrimaryProgression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer.

Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
For participants enrolled in the Phase 2 portion, outcome is from the date of starting chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Reported as:
Median · Number of months
Progression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer.
Number of monthsPhase 2 - Cohort A Platinum-resistant ParticipantsPhase 2 - Cohort A Platinum-refractory ParticipantsPhase 2 - Cohort C Platinum-resistant ParticipantsPhase 2 - Cohort C Platinum-refractory Participants
Progression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer.10 (4.0 to NA)10.3 (4.3 to NA)11 (5.2 to NA)10.1 (1.1 to 11.5)
PrimaryOverall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer

To assess anti-tumor response by Overall Response Rate by Tumor Marker Cancer Antigen-125 (CA-125) for participants who were enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer.

Time frame:
Assessed pre-treatment, during treatment at 2- to 3-week intervals and post-treatment assessed up to 24 months.
Reported as:
Number · Percent of participants
Overall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer
Percent of participantsPhase 2 - Cohort A Platinum-resistant ParticipantsPhase 2 - Cohort A Platinum-refractory ParticipantsPhase 2 - Cohort C Platinum-resistant ParticipantsPhase 2 - Cohort C Platinum-refractory Participants
Overall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer80.066.775.085.7
PrimaryOverall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer

To assess anti-tumor response by Overall Response Rate (ORR) defined as disease control rate (DCR = CR + PR + SD≥15 weeks) by RECIST 1.1 criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.

Time frame:
For evaluable participants enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer who were assessed at pre-treatment, during treatment at 6- to 12-week intervals and post-treatment up to 24 months.
Reported as:
Number · Percent of participants
Overall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer
Percent of participantsPhase 2 - Cohort A Platinum-resistant ParticipantsPhase 2 - Cohort A Platinum-refractory ParticipantsPhase 2 - Cohort C Platinum-resistant ParticipantsPhase 2 - Cohort C Platinum-refractory Participants
Overall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer87.533.333.360.0
SecondaryEvaluation of Tumor Response to Treatment for Participants Enrolled in the Phase 1b Portion of This Study

Participants enrolled in the Phase 1b study were assessed for best overall response to treatment with therapeutic intent by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.

Time frame:
Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.
Reported as:
Count of participants · Participants
Evaluation of Tumor Response to Treatment for Participants Enrolled in the Phase 1b Portion of This Study
ParticipantsPhase 1b - Cohort 1Phase 1b - Cohort 2
Complete Response00
Partial Response11
Stable Disease10
Progressive Disease00
Unevaluable00
SecondaryCA-125 Response in Participants Enrolled in the Phase 1b Portion of This Study

CA-125 according to the Gynecologic Cancer Intergroup (GCIG) is measured by at least a 50% reduction in CA-125 levels from pre-treatment sample which is confirmed and maintained for at least 28 days. Pre-treatment CA-125 sample must be at least twice the upper limit of normal and obtained within 2 weeks prior to starting treatment.

Time frame:
Assessed pre-treatment, during treatment and post-treatment at 6 to 12 week intervals, assessed up to 24 months.
Reported as:
Count of participants · Participants
CA-125 Response in Participants Enrolled in the Phase 1b Portion of This Study
ParticipantsPhase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 Participants
CA-125 Response in Participants Enrolled in the Phase 1b Portion of This Study21
SecondaryDetermine Progression-free Survival Following Treatment (Phase 1b)

To assess the number of months of progression-free survival (PFS) by RECIST 1.1.

Time frame:
From the date of starting chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Reported as:
Median · Number of months
Determine Progression-free Survival Following Treatment (Phase 1b)
Number of monthsPhase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 Participants
Determine Progression-free Survival Following Treatment (Phase 1b)11.6 (11.6 to NA)16.7 (16.7 to 16.7)
SecondaryOverall Survival

To determine overall survival (OS) in the participant population.

Time frame:
By medical chart review until death or 3 years from the date of last treatment whichever comes first.
Reported as:
Median · Number of months
Overall Survival
Number of monthsPhase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C Participants
Overall Survival33.6 (33.6 to NA)61.7 (61.7 to NA)18.5 (11.3 to 23.8)12.7 (3.2 to 15.7)
SecondaryClinical Benefit Rate

Defined as the percentage of patients who have achieved CR + PR + SD by RECIST 1.1.

Time frame:
Approximately 24 months
Reported as:
Number · Percent of participants
Clinical Benefit Rate
Percent of participantsPhase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C Participants
Clinical Benefit Rate10010091100
Other pre-specifiedEvaluation of Immune-related Tumor Response

This exploratory outcome measure evaluates participants' best overall response to treatment with oncolytic immunotherapy assessed by Immune-related Response Criteria (immune-related complete response, immune-related partial response, immune-related stable disease, or immune-related progressive disease).

Time frame:
Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.

No measurements were reported for this outcome.

Adverse events

Collected over During GL-ONC1 treatment and until the 30-day Post-treatment for an average of 2 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b - Cohort 15/6 (83.3%)2/6 (33.3%)5/6 (83.3%)
Phase 1b - Cohort 25/5 (100%)1/5 (20%)5/5 (100%)
Phase 1b - Cohort 31/1 (100%)0/1 (0%)1/1 (100%)
Phase 2 - Cohort A22/22 (100%)5/22 (22.7%)22/22 (100%)
Phase 2 - Cohort C11/12 (91.7%)2/11 (18.2%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventPhase 1b - Cohort 1Phase 1b - Cohort 2Phase 1b - Cohort 3Phase 2 - Cohort APhase 2 - Cohort C
PyrexiaGeneral disorders0/61/50/10/220/11
Abdominal painGastrointestinal disorders1/60/50/11/220/11
VomitingGastrointestinal disorders1/60/50/13/220/11
AstheniaGeneral disorders1/60/50/10/220/11
DehydrationMetabolism and nutrition disorders1/60/50/10/220/11
NauseaGastrointestinal disorders0/60/50/10/221/11
FatigueGeneral disorders0/60/50/10/221/11
Decreased appetiteMetabolism and nutrition disorders0/60/50/11/220/11
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPhase 1b - Cohort 1Phase 1b - Cohort 2Phase 1b - Cohort 3Phase 2 - Cohort APhase 2 - Cohort C
Abdominal distensionGastrointestinal disorders0/64/51/115/223/11
AscitesGastrointestinal disorders0/62/51/11/221/11
ChillsGeneral disorders2/65/50/15/225/11
PyrexiaGeneral disorders2/63/50/115/228/11
Abdominal painGastrointestinal disorders2/61/50/115/225/11
NauseaGastrointestinal disorders4/63/50/115/222/11
FatigueGeneral disorders2/61/50/18/224/11
VomitingGastrointestinal disorders2/60/50/15/222/11
HeadacheNervous system disorders2/60/50/11/222/11
SomnolenceNervous system disorders2/60/50/10/220/11

Baseline characteristics

Participants who received at least 1 dose of Olvi-Vec.

Age, Categorical
Age, Categorical(Participants)Phase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C ParticipantsTotal
<=18 years000000
Between 18 and 65 years23015828
>=65 years4217418
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C ParticipantsTotal
Female651221246
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C ParticipantsTotal
Hispanic or Latino000347
Not Hispanic or Latino65119839
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C ParticipantsTotal
American Indian or Alaska Native000000
Asian000101
Native Hawaiian or Other Pacific Islander000000
Black or African American100001
White551211143
More than one race000000
Unknown or Not Reported000011
Region of Enrollment
Region of Enrollment(Participants)Phase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C ParticipantsTotal
United States651221246
Platinum Disease
Platinum Disease(Participants)Phase 1b - Cohort 1 ParticipantsPhase 1b - Cohort 2 ParticipantsPhase 1b - Cohort 3 ParticipantsPhase 2 - Cohort A ParticipantsPhase 2 - Cohort C ParticipantsTotal
Platinum-resistant ovarian cancer43114527
Platinum-refractory ovarian cancer2206717
Intermediate platinum-sensitive ovarian cancer000202
08

Study locations

2 sites
  • Gynecologic Oncology Associates
    Newport Beach, California 92663, United States
  • AdventHealth Cancer Institute
    Orlando, Florida 32804, United States
09

References and documents

Publications

  • Yu YA, Holloway RW, Mendivil AA, Ahmad S. Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer. Gynecol Oncol Rep. 2026 Jun 19;66:102145. doi: 10.1016/j.gore.2026.102145. eCollection 2026 Aug. PubMed 42383154 ↗
  • Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007. PubMed 37227734 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Dec 2021 and a completion of Dec 2022. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2026, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2016
First posted
May 3, 2016
Start
May 2016
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2022
Results first posted
Jun 12, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02759588
Lead sponsor
Genelux Corporation
Responsible party
Sponsor
First posted
May 3, 2016
Start date
May 2016
Primary completion
Dec 31, 2021
Completion
Dec 31, 2022
Results posted
Jun 12, 2026
Last update
Jun 12, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olvimulogene nanivacirepvec

Start the discussion